Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights
Celyad Oncology (CYAD) reported its H1 2024 financial results and business highlights. The company is focusing on research and development, particularly in intellectual property monetization. Key developments include:
1. Proof-of-concept for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform.
2. Active participation in scientific conferences and publications in peer-reviewed journals.
3. Re-initiation of C-Cath® manufacturing and commercialization.
4. Cash runway extended until Q3 2025.
Financial highlights:
- R&D expenses: €1.5M (down from €2.1M in H1 2023)
- G&A expenses: €1.7M (down from €3.7M in H1 2023)
- Net loss: €3.0M (€0.07 per share)
- Cash position: €6.2M as of June 30, 2024
Celyad Oncology (CYAD) ha riportato i risultati finanziari e i principali sviluppi aziendali per il primo semestre del 2024. L'azienda è focalizzata sulla ricerca e sviluppo, in particolare sulla monetizzazione della proprietà intellettuale. I principali sviluppi includono:
1. Prova di concetto per la tecnologia multiplex shRNA non modificata e la piattaforma CAR T-cell basata su NKG2D multispecifici.
2. Partecipazione attiva a conferenze scientifiche e pubblicazioni su riviste peer-reviewed.
3. Riapertura della produzione e commercializzazione di C-Cath®.
4. Estensione della liquidità fino al terzo trimestre del 2025.
Risultati finanziari:
- Spese R&S: €1,5M (in calo rispetto a €2,1M nel primo semestre del 2023)
- Spese generali e amministrative: €1,7M (in calo rispetto a €3,7M nel primo semestre del 2023)
- Perdita netta: €3,0M (€0,07 per azione)
- Posizione di liquidità: €6,2M al 30 giugno 2024
Celyad Oncology (CYAD) informó sobre sus resultados financieros y aspectos destacados del negocio para el primer semestre de 2024. La compañía está enfocándose en la investigación y el desarrollo, particularmente en la monetización de propiedad intelectual. Los desarrollos clave incluyen:
1. Prueba de concepto para la tecnología multiplex shRNA no editada y la plataforma de células T CAR basada en NKG2D multispecífica.
2. Participación activa en conferencias científicas y publicaciones en revistas revisadas por pares.
3. Reanudación de la fabricación y comercialización de C-Cath®.
4. Extensión de la disponibilidad de efectivo hasta el tercer trimestre de 2025.
Aspectos financieros destacados:
- Gastos en I+D: €1,5M (bajó de €2,1M en el primer semestre de 2023)
- Gastos generales y administrativos: €1,7M (bajó de €3,7M en el primer semestre de 2023)
- Pérdida neta: €3,0M (€0,07 por acción)
- Posición de efectivo: €6,2M a partir del 30 de junio de 2024
Celyad Oncology (CYAD)는 2024년 상반기 재무 결과와 사업 하이라이트를 발표했습니다. 이 회사는 연구 및 개발에 집중하고 있으며, 특히 지적 재산의 수익화에 힘쓰고 있습니다. 주요 개발 사항은 다음과 같습니다:
1. 다중 shRNA 비유전자 편집 기술과 다특이적 NKG2D 기반 CAR T 세포 플랫폼의 개념 증명.
2. 과학 회의에 적극 참여하고 동료 심사 저널에 논문 발표.
3. C-Cath® 제조 및 상용화 재개.
4. 현금 유통 기한이 2025년 3분기까지 연장됨.
재무 하이라이트:
- 연구개발비: €1.5M (2023년 상반기 €2.1M에서 감소)
- 일반 관리비: €1.7M (2023년 상반기 €3.7M에서 감소)
- 순손실: €3.0M (€0.07 주당)
- 현금 보유액: 2024년 6월 30일 기준 €6.2M
Celyad Oncology (CYAD) a publié ses résultats financiers et les points saillants de ses activités pour le premier semestre 2024. L'entreprise se concentre sur la recherche et le développement, en particulier sur la monétisation de la propriété intellectuelle. Les développements clés comprennent :
1. Preuve de concept pour la technologie multiplex shRNA non modifiée et la plateforme CAR T-cell basée sur NKG2D multispecifique.
2. Participation active à des conférences scientifiques et publications dans des revues à comité de lecture.
3. Réouverture de la fabrication et de la commercialisation de C-Cath®.
4. Prolongation de la trésorerie jusqu'au troisième trimestre 2025.
Points financiers saillants :
- Dépenses R&D : 1,5 M€ (en baisse par rapport à 2,1 M€ au premier semestre 2023)
- Dépenses G&A : 1,7 M€ (en baisse par rapport à 3,7 M€ au premier semestre 2023)
- Perte nette : 3,0 M€ (0,07 € par action)
- Position de trésorerie : 6,2 M€ au 30 juin 2024
Celyad Oncology (CYAD) hat die finanziellen Ergebnisse und Geschäftshighlights für das erste Halbjahr 2024 berichtet. Das Unternehmen konzentriert sich auf Forschung und Entwicklung, insbesondere auf die Monetarisierung von geistigem Eigentum. Zu den wichtigsten Entwicklungen gehören:
1. Machbarkeitsnachweis für die Multiplex-shRNA-nicht-genbearbeitete Technologie und die multispezifische NKG2D-basierte CAR-T-Zell-Plattform.
2. Aktive Teilnahme an wissenschaftlichen Konferenzen und Veröffentlichungen in Fachzeitschriften.
3. Wiederaufnahme der Herstellung und Vermarktung von C-Cath®.
4. Liquiditätslaufzeit bis zum dritten Quartal 2025 verlängert.
Finanzielle Höhepunkte:
- F&E-Ausgaben: €1,5M (im Vergleich zu €2,1M im ersten Halbjahr 2023 gesunken)
- Allgemeine und Verwaltungskosten: €1,7M (im Vergleich zu €3,7M im ersten Halbjahr 2023 gesunken)
- Nettoverlust: €3,0M (€0,07 pro Aktie)
- Liquiditätsposition: €6,2M zum 30. Juni 2024
- Proof-of-concept achieved for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform
- Cash runway extended until Q3 2025
- Reduction in R&D expenses from €2.1M to €1.5M year-over-year
- Decrease in G&A expenses from €3.7M to €1.7M year-over-year
- Net cash used in operations reduced from €8.3M to €2.8M compared to H1 2023
- Net loss of €3.0M for H1 2024
- Decrease in cash position from €7.0M at end of 2023 to €6.2M as of June 30, 2024
Insights
Celyad Oncology's H1 2024 results reveal a strategic shift towards research and IP monetization. The company's
Celyad's strategic pivot towards research platforms shows promise. Their multiplex shRNA technology for simultaneous gene knockdown in CAR T-cells addresses key challenges in allogeneic therapies, potentially improving cell viability and persistence. The multispecific NKG2D-based CAR T-cell platform, demonstrating efficacy against heterogeneous tumors, could be a game-changer for treating antigen loss in cancers. These innovations position Celyad well in the competitive CAR T-cell therapy landscape. However, the transition from clinical to preclinical focus is a double-edged sword - it reduces immediate clinical risks but also delays potential market entry. The success of this strategy hinges on Celyad's ability to secure valuable partnerships and licensing deals in the near future.
Celyad's shift to a research-focused model reflects broader industry trends where small biotechs are leveraging their IP and platforms rather than pursuing costly clinical development. The reintroduction of C-Cath® for cardiac applications shows opportunistic diversification. However, investor sentiment may be mixed due to the lack of near-term clinical catalysts. The company's presence at key scientific conferences and publications in peer-reviewed journals could help maintain interest from potential partners. The anticipated appointment of a new CEO in H2 2024 may bring fresh perspectives and potentially new strategic directions. Celyad's success will largely depend on its ability to translate scientific advancements into tangible partnerships or licensing deals in the competitive cell therapy space.
- The Company continues to bolster its intellectual property estate and to pursue options to monetize it
- The Company’s two main research and development platforms have delivered proof-of-concept and are ready to be incorporated into clinical candidates and/or to be further explored and exploited via potential partnerships
- The Company actively participated at several key international scientific conferences and published in well-renowned peer-reviewed journals which have raised the interest for the Company’s technologies and developments
- Operational expenses according to Budget allowing cash runway until third quarter 2025
MONT-SAINT-GUIBERT,
Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the first half year 2024 ended June 30, 2024, and provides a business update.
Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “Celyad Oncology continues to make remarkable progress in developing cutting-edge technologies for chimeric antigen receptor (CAR) T-cell therapy. Our groundbreaking multiplex platform is revolutionizing the potential of CAR T-cells, while our pioneering NKG2D-based multispecific CAR T-cell platform is further paving the way to conquer current limitations of this transformative class of immunotherapy.”
H1-2024 Business highlights
- The Company is pursuing a strategy of continued research and development, with a particular focus on intellectual property (IP). Monetization of its innovative approaches and technologies is a key objective. Celyad Oncology is progressing in this regard and is currently in discussion with potential partners for out-licensing deals;
- With its research focus, the Company has made concrete progress by providing proof-of-concept of the multiplex short hairpin RNAs (shRNAs) non-gene edited technology platform and the multispecific NKG2D-based CAR T-cell platform, which provide unique options to tackle the major current limitations of CAR T-cell therapies. Options to further explore or validate these data through strategic partnerships, and/or to incorporate these technologies into clinical CAR-T candidates are actively pursued by the Company;
- The Company continues to share and discuss its latest advances at international scientific conferences throughout the first half of 2024 with updated results provided at the 27th ASGCT 1 Annual Meeting and the Recent insights into Immuno-Oncology VIB conference 2.
- The Company is also focusing on sharing data and views with the scientific community and has published a review highlighting the interest of non-gene editing technologies for allogeneic CAR T-cell therapies in Cells 3 and another review providing an overview of all engineering strategies to safely drive CAR T-cells into the future in Frontiers in Immunology 4, two well-renowned peer-reviewed scientific journals;
- In response to the request expressed by several companies and academic institutions engaged in gene and cell therapies for cardiac applications, the Company has re-initiated the manufacturing and commercialization of C-Cath®, an intra-myocardial injection catheter developed and owned by the Company.
H1-2024 operational highlights
-
Multiplex shRNA non-gene edited technology – The Company developed a chimeric micro-RNA (miRNA) cluster to enable multiplexing of shRNAs, designed for easy, efficient, and tunable downregulation of up to four target genes simultaneously in CAR T-cells.
- Data successfully demonstrated the feasibility and effectiveness of the multiplex approach to improve allogeneic CAR T-cell viability by avoiding graft-versus-host disease (GvHD) via knocking down of CD3ζ, avoiding host-versus-graft (HvG) reaction and promoting cell persistence via knocking-down of β2M and CIITA, and avoiding CD95L-induced autophagy via knocking-down of CD95;
- Another multiplex cassette focusing on the knock-down of co-inhibitory receptors (PD-1, LAG-3, TIM-3 and CD95) was also developed to decrease the expression of exhaustion markers at the surface of CAR T-cells.
-
Multispecific NKG2D-based CAR T-cell platform – Different NKG2D-based multispecific CAR T-cells were developed to provide the proof-of-concept that NKG2D ligands (NKG2DL) are valuable targets in a multispecific CAR approach to counteract relapses due to antigen loss or antigen heterogeneity.
- PSMA/NKG2DL tandem CAR T-cells, that encompass the extracellular domain of the natural NKG2D receptor fused to an anti-PSMA CAR to overcome antigen heterogeneity and improve anti-tumor efficacy against prostate cancer were developed and demonstrated functionality in vitro against prostate cancer cell lines expressing or not the tumor-associated antigen PSMA;
- In vivo proof-of-concept of the company’s CD19/NKG2DL tandem CAR T-cell candidate was also provided in a B-ALL relapse model, showing that this multi-specific CAR T-cell candidate has an enhanced anti-tumor efficacy against heterogeneous lymphoma tumors, or to counteract antigen loss, as compared to currently existing treatment options.
First Half 2024 financial review
As of June 30, 2024, the Company’s Treasury position amounts to
After due consideration of detailed budgets and estimated cash flow forecasts for the years 2024 and 2025, the Company projects that its existing cash and cash equivalents will be sufficient to fund its estimated operating and capital expenditures into the third quarter of 2025.
Key financial figures for first half 2024, compared with the first half of 2023 and full year 2023, are summarized below:
Selected key financial figures (€ millions) |
Half Year
|
Half Year
|
Full Year
|
Revenue |
- |
- |
0.1 |
Research and development expenses |
(1.5) |
(2.1) |
(4.6) |
General and administrative expenses |
(1.7) |
(3.7) |
(6.0) |
Change in fair value of contingent consideration |
- |
- |
0 |
Impairment of Oncology intangible assets |
- |
- |
0 |
Other income/(expenses) |
0.2 |
2.1 |
2.1 |
Operating loss |
(3.1) |
(3.7) |
(8.5) |
Loss for the period/year |
(3.0) |
(3.7) |
(8.5) |
Net cash used in operations |
(2.8) |
(8.3) |
(15.2) |
Cash and cash equivalents |
6.2 |
5.0 |
7.0 |
Research and Development (R&D) expenses were
General and Administrative (G&A) expenses were
As of June 30, 2024, Management has determined that there has been no event (such as a firm sublicense or collaboration contract) that led to a change in fair value of the contingent consideration and other financial liabilities. The Company’s other income is mainly associated with grants received and some insurance compensations.
Net loss for the first half of 2024, was
Net cash used in operations was
Upcoming anticipated milestones
- More data and evidence in the context of the multispecific CAR and shRNA multiplex platforms, with the possibility of a clinical evaluation of assets and initiation of clinical trials either by the Company and/or through strategic partnerships afterwards;
-
Celyad Oncology will attend and present updated data on its programs at the 9th CAR-TCR Summit in
Boston , US (Sep. 17-20), the Advanced Therapies Europe in Estoril (Sep. 10-12) and present two posters at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) inHouston (Nov. 6-10); - The Company anticipates the appointment of a new CEO in the second half of 2024.
Financial Calendar 2025
- April 2nd 2025 : Full Year 2024 Financial Statements
- May 5th 2025 : Annual shareholders meeting
- September 25th 2025 : First Half 2025 Interim results
The financial calendar is communicated on an indicative basis and may be subject to change.
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert,
Celyad Oncology Forward-Looking Statement
This release may contain forward-looking statements, including, without limitation, statements regarding beliefs about and expectations for the Company’s updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Company’s IP, statements regarding the Company’s financial statements and cash runway, statements regarding the Company’s future fundraising plans, statements regarding the Company’s hiring plans, and statements regarding the continuation of the Company’s existence. The words “will,” “potential,” “continue,” “target,” “project,” “should” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on management’s current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to the material uncertainty about the Company’s ability to continue as a going concern; the Company’s ability to realize the expected benefits of its updated strategic business model; the Company’s ability to develop its IP assets and enter into partnerships with outside parties; the Company’s ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Company’s ability to protect its IP rights throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in the latest Annual Report and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Source: Celyad Oncology SA
Celyad Oncology SA
Consolidated Statement of Comprehensive Loss
(€'000) |
|
For the Six-month period ended June 30, |
|
|
2024 |
2023 |
|
Revenue |
|
14 |
44 |
Cost of sales |
|
(9) |
(44) |
Gross profit |
|
5 |
- |
Research and Development expenses |
|
(1 537) |
(2 139) |
General & Administrative expenses |
|
(1 737) |
(3 665) |
Other income |
|
222 |
2 123 |
Other expenses |
|
(37) |
(64) |
Operating Loss2 |
|
(3 083) |
(3 745) |
Financial income |
|
100 |
26 |
Financial expenses |
|
(61) |
(21) |
Loss before taxes |
|
(3 044) |
(3 740) |
Income taxes |
|
- |
- |
Loss for the period |
|
(3 044) |
(3 740) |
Basic and diluted loss per share (in €) |
|
(0,07) |
(0,17) |
Celyad Oncology SA
Consolidated Statement of Financial Position
(€’000) |
|
June 30, |
December 31, |
|
2024 |
2023 |
|
NON-CURRENT ASSETS |
|
4 183 |
5 161 |
Goodwill and Intangible assets |
|
453 |
390 |
Property, Plant and Equipment |
|
1 669 |
1 830 |
Non-current Grant receivables |
|
1 946 |
2 804 |
Other non-current assets |
|
115 |
137 |
CURRENT ASSETS |
|
8 663 |
11 121 |
Trade and Other Receivables |
|
113 |
457 |
Current Grant receivables |
|
892 |
2 258 |
Other current assets |
|
1 428 |
1 402 |
Cash and cash equivalents |
|
6 229 |
7 004 |
TOTAL ASSETS |
|
12 846 |
16 282 |
EQUITY |
|
3 265 |
6 304 |
Share Capital |
|
8 216 |
32 949 |
Share premium |
|
- |
- |
Other reserves |
|
35 741 |
35 734 |
Capital reduction reserve |
|
320 726 |
295 993 |
Accumulated deficit |
|
(361 417) |
(358 372) |
NON-CURRENT LIABILITIES |
|
7 165 |
7 046 |
Lease liabilities |
|
834 |
902 |
Recoverable Cash advances (RCAs) |
|
4 601 |
4 505 |
Post-employment benefits |
|
1 |
1 |
Other non-current liabilities |
|
1 729 |
1 638 |
CURRENT LIABILITIES |
|
2 416 |
2 932 |
Lease liabilities |
|
155 |
156 |
Recoverable Cash advances (RCAs) |
|
302 |
366 |
Trade payables |
|
1 060 |
1 243 |
Other current liabilities |
|
898 |
1 167 |
TOTAL EQUITY AND LIABILITIES |
|
12 846 |
16 282 |
_____________________
1 American Society of Gene & Cell Therapy Annual meeting,
2 Recent insights into Immuno-Oncology VIB (Flemish Institute for Biotechnology) conference,
3 Cells 2024;13(2):146
4 Front Immunol. 2024:15:1411393
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912537151/en/
Investor & Media Contact:
David Georges, VP Finance and Administration
investors@celyad.com
Source: Celyad Oncology SA
FAQ
What were Celyad Oncology's (CYAD) key financial results for H1 2024?
What are the main research platforms Celyad Oncology (CYAD) is focusing on?
How long is Celyad Oncology's (CYAD) cash runway expected to last?